Pharmaceutical preparations containing (+)-cyanidan-3-ol derivatives, the use thereof, novel substituted (+)-cyanidan-3-ol derivatives, and processes for producing them
申请人:Zyma SA
公开号:EP0096007A2
公开(公告)日:1983-12-07
Pharmaceutical preparations containing (+)-cyanidan-3-ol derivatives of the formula I
wherein R' and R" are hydrogen, an unsubstituted or substituted hydrocarbon radical, or heterocyclic radical, halogen, formyl, free or functionally modified carboxyl, free or etherified or esterified hydroxyl, free, etherified or oxidized mercapto, unsubstituted or substituted sulfamoyl, acyl or unsubstituted or substituted amino, where however R' and R" cannot both be hydrogen simultaneously, and R1, R2, R3, R4 and R5 are each hydrogen or an unsubstituted or substituted hydrocarbon radical, and R2 and R3 together can also be an unsubstituted or substituted methylene group, and R1 also an acyl group or an amidated carboxyl group; and therapeutically applicable salts of these compounds, as well as new compounds of these preparations.
These pharmaceutical preparations are particularly valuable for treating liver and venous diseases.
含有式 I 的(+)-花青素-3-醇衍生物的药物制剂
其中 R'和 R "为氢、未取代或取代的烃基、或杂环基、卤素、甲酰基、游离或功能修饰的羧基、游离或醚化或酯化的羟基、游离、醚化或氧化的巯基、未取代或取代的氨基磺酰基、酰基或未取代或取代的氨基、其中,R'和 R "不能同时为氢,R1、R2、R3、R4 和 R5 各为氢或未取代或取代的烃基,R2 和 R3 也可以是未取代或取代的亚甲基,R1 也可以是酰基或酰胺化羧基;以及这些化合物的治疗盐和这些制剂的新化合物。
这些药物制剂对治疗肝脏和静脉疾病特别有价值。